Readystate Asset Management LP bought a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 287,000 shares of the company's stock, valued at approximately $1,332,000. Readystate Asset Management LP owned about 0.47% of Monte Rosa Therapeutics at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Monte Rosa Therapeutics by 192.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock valued at $38,000 after purchasing an additional 3,584 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at $43,000. Virtus ETF Advisers LLC purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at $63,000. Focus Partners Wealth purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at $77,000. Finally, Invesco Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at $89,000. 79.96% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen cut shares of Monte Rosa Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd.
View Our Latest Stock Analysis on Monte Rosa Therapeutics
Monte Rosa Therapeutics Price Performance
Monte Rosa Therapeutics stock traded down $0.04 during mid-day trading on Friday, hitting $5.67. The company's stock had a trading volume of 236,003 shares, compared to its average volume of 433,018. The firm's 50 day moving average is $4.84 and its 200 day moving average is $5.22. The company has a market cap of $348.76 million, a PE ratio of 70.88 and a beta of 1.41. Monte Rosa Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $12.40.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.81. The firm had revenue of $84.93 million during the quarter, compared to the consensus estimate of $13.57 million. Monte Rosa Therapeutics had a return on equity of 2.65% and a net margin of 3.86%. As a group, analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.
Monte Rosa Therapeutics Profile
(
Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Articles
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access